Remission of acromegaly after treatment withdrawal in patients controlled by cabergoline alone or in combination with octreotide: results from a multicenter study

[1] Ronchi CL(2008)Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal Eur J Endocrinol 158 19-25

[2] Rizzo E(2012)Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: Is it worth trying? Eur J Endocrinol 166 21-26

[3] Lania AG(2014)Montenegro RM Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial Endocrine 46 577-584

[4] Pivonello R(2015)Discontinuation of somatostatin analogs while acromegaly is in long-term remission Pituitary 18 554-560

[5] Grottoli S(2008)Remission of acromegaly following long-term therapy with cabergoline: report of two cases Pituitary 11 103-107

[6] Colao A(2011)Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 96 273-288

[7] Ghigo E(2010)Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis J Clin Endocrinol Metab 95 43-51

[8] Spada A(2010)Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling IGF-I levels in acromegaly Neuroendocrinology 92 120-127

[9] Arosio M(2011)Place of cabergoline in acromegaly: a meta-analysis J Clin Endocrinol Metab 96 1327-1335

[10] Beck-Peccoz P(2009)Guidelines for acromegaly management: an update J Clin Endocrinol Metab 94 1509-1517

[1] Ronchi CL(2008)Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal Eur J Endocrinol 158 19-25

[2] Rizzo E(2012)Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: Is it worth trying? Eur J Endocrinol 166 21-26

[3] Lania AG(2014)Montenegro RM Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial Endocrine 46 577-584

[4] Pivonello R(2015)Discontinuation of somatostatin analogs while acromegaly is in long-term remission Pituitary 18 554-560

[5] Grottoli S(2008)Remission of acromegaly following long-term therapy with cabergoline: report of two cases Pituitary 11 103-107

[6] Colao A(2011)Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 96 273-288

[7] Ghigo E(2010)Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis J Clin Endocrinol Metab 95 43-51

[8] Spada A(2010)Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling IGF-I levels in acromegaly Neuroendocrinology 92 120-127

[9] Arosio M(2011)Place of cabergoline in acromegaly: a meta-analysis J Clin Endocrinol Metab 96 1327-1335

[10] Beck-Peccoz P(2009)Guidelines for acromegaly management: an update J Clin Endocrinol Metab 94 1509-1517